CO-RADIA
18.7.2024 15:01:36 CEST | Business Wire | Press release
Three aerospace leaders – Aernnova, Leonardo and AFuzion – will partner with Radia on WindRunner™, the world’s largest aircraft. Radia is developing WindRunner to deliver the largest, most efficient wind turbine blades, expand the reach of wind energy and transform its economics, enabling the world to meet its climate goals.
The companies are joining Radia’s innovation ecosystem. They will be available to discuss the partnerships at the 2024 Farnborough International Airshow.
Aernnova will partner with Radia on the development of the aircraft’s wing and engine pylons. Leonardo will develop the fuselage. AFuzion will provide safety and certification consulting.
The partnership agreements are the latest step forward for WindRunner, an aircraft designed for its primary mission: To fly large turbine blades – up to 105m in length, longer than a football pitch – directly to wind farm sites, landing on semi-prepared dirt runways as short as 1,800m (6,000 ft). It will overcome logistical barriers that today prevent the expansion of onshore wind energy. Wind turbines become more effective and efficient the larger they are. But long turbine blades are extremely difficult and expensive to move by ground transport because literal roadblocks – bridges, tunnels and road curves – get in the way.
WindRunner will fly over these roadblocks, enabling the deployment of the largest, most efficient onshore wind turbines today and the even larger ones of the future – what Radia calls GigaWind™.
The result will be widespread availability of consistent, lowest-cost clean energy in more locations and at industrial scale for the grid, green fuel production including sustainable aviation fuel (SAF), and commercial power users such as data centers and hyperscalers. The market for onshore wind energy is estimated at up to $10 trillion by 2050 – as many as 1 million wind turbines.
Partners Will Help Radia Fulfill Its Mission and Can Seize a New Opportunity for Aerospace
“WindRunner is an opportunity for the aerospace industry to have a decisive impact on climate change, diversify into the energy industry and seize an enormous market opportunity,” said Mark Lundstrom, Radia’s CEO. “We are extremely pleased and excited that Aernnova, Leonardo and AFuzion – three companies at the forefront of aerospace design, development, and engineering – have chosen to partner with us on this critically important project.”
Partners Attracted by Scope and Ambition of Project, Importance of its Goals, Say Aernnova, Leonardo and AFuzion Executives
“We are excited and proud to participate in the world’s largest aircraft, especially in view of its mission,” said Ricardo Chocarro, CEO of Aernnova. “Based on my previous experience in this sector of the wind turbine industry, I can affirm the importance of the solution that WindRunner provides. The agreement with Radia for the development of the WindRunner project positions us in the wing and engine pylon design and manufacturing support, recognizing our expertise for the design and development of this ambitious project.”
Stefano Bortoli, Leonardo Aerostructures Division MD, said: “The WindRunner initiative is an interesting example of how the aerospace industry continues to provide a key contribution to sustainability, with a range of diversified solutions to the benefit of multiple sectors. Also, Leonardo has a deep experience in the energy sector with its technologies in aviation, including wind farms. Therefore, it gives us great pleasure to support this initiative with our established aerostructure engineering know-how and capabilities.”
“WindRunner must operate safely in a wide range of operating environments,” said AFuzion CEO Vance Hilderman. “And the urgency of the climate crisis demands that it move systematically through the certification process so that it can enter into service. AFuzion is eager to bring our capabilities to bear to support WindRunner’s progress from design all the way through to deployment.”
Aerospace Can Help Make Renewables Viable and Climate Goals Achievable
“WindRunner is exciting and consequential,” said Lundstrom, “not only because of the scope of the project but also because of its critical importance to the viability and the economics of renewable energy and society’s ability to meet our growing need for power while achieving our climate goals. Our partnership with Aernnova, Leonardo and AFuzion will enable us to deliver on that promise, fulfill our mission, and achieve a significant impact on renewables.”
About Radia
Radia is an energy company building a unique aerial transportation solution, the WindRunner, to radically expand the scope and scale of the onshore wind energy industry. Simultaneously, Radia is developing a world-class portfolio of wind energy projects to leverage this solution and partnering with the world’s largest energy and industrial companies to support their energy transition plans. This unique combination of capabilities allows Radia to bring together the ecosystem of stakeholders and partners to enable GigaWind – the largest onshore wind turbines manufactured by our partners deployed to more places to deliver differentiated low-cost clean electricity and, correspondingly, green molecules and synthetic fuels. Radia has been selected both as a World Economic Forum Global Unicorn and as an Endeavor Entrepreneur in their competitive International Selection Panel process. For more information: www.radia.com.
About Aernnova
Aernnova is a leading company specialized in the design, manufacturing, maintenance, and services of aerostructures and their components such as wings, empennages, fuselages, stabilizers, bulkheads, doors and moving surfaces for the world's leading aircraft manufacturers. Aernnova is a company committed to sustainability, technological development and digitization. Headquartered in Spain, Aernnova is among the world's leading Tier 1 aerostructures suppliers with a global presence through its manufacturing and engineering facilities in Spain, U.K., U.S.A., Portugal, Mexico and Brazil. More information about Aernnova can be found in: www.aernnova.com
About Leonardo
Leonardo is an international industrial group, among the main global companies in Aerospace, Defence, and Security (AD&S). With 53,000 employees worldwide, the company approaches global security through the Helicopters, Electronics, Aircraft, Cyber & Security and Space sectors, and is a partner on the most important international programmes, within these sectors, such as Eurofighter, NH-90, FREMM, GCAP, and Eurodrone. Leonardo has significant production capabilities in Italy, the UK, Poland, and the USA. Leonardo utilises its subsidiaries, joint ventures, and shareholdings, which include Leonardo DRS (72.3%), MBDA (25%), ATR (50 %), Hensoldt (22.8%), Telespazio (67%), Thales Alenia Space (33%), and Avio (29.6%). Listed on the Milan Stock Exchange (LDO), in 2023 Leonardo recorded new orders for €17.9 billion, with an order book of €39.5 billion and consolidated revenues of €15.3 billion. Included in the MIB ESG index, the company has also been part of the Dow Jones Sustainability Indices (DJSI) since 2010. More information about Leonardo can be found in: www.leonardo.com
About AFuzion
AFuzion specializes in avionics certification training and consulting, providing comprehensive solutions to help companies navigate complex regulatory requirements. With a focus on DO-254, AC 20-152A, and A(M)C 20-152A compliance, AFuzion's expert team offers invaluable guidance and training to ensure the development of reliable and safe avionics hardware.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718714101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom